atbtherapeutics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 36

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $60M

  • Investors
  • 14

atbtherapeutics General Information

Description

Developer of antibody-based targeted therapy from plant cells designed to provide novel therapeutic treatment for patients with hard-to-treat cancer. The company offers antibodies with a new class of immunotherapy, which is a biologic format aimed at expanding the therapeutic window for treatment, enabling healthcare practitioners to use the combination of a new bioprocess with novel targeted therapies to help cancer patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Novalis Science Park
  • Rue De La Science, 8
  • 6900 Aye
  • Belgium
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Novalis Science Park
  • Rue De La Science, 8
  • 6900 Aye
  • Belgium

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

atbtherapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series A) 01-Oct-2024 $60M Completed Generating Revenue
3. Seed Round 17-Dec-2019 Completed Generating Revenue
2. Seed Round 01-Jan-2018 $1.78M $1.78M Completed Startup
1. University Spin-Out 01-Jan-2018 Completed Startup
To view atbtherapeutics’s complete valuation and funding history, request access »

atbtherapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
Series A
Class C
Class B
Class A 5,082 $9.84 $9.84 1x $9.84 0.13%
Ordinary 124,000 $6.1 $6.1 1x $6.1 3.27%
To view atbtherapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

atbtherapeutics Patents

atbtherapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023322567-A1 Humanized antibodies against cd79b Pending 08-Aug-2022
EP-4568997-A1 Humanized antibodies against cd79b Pending 08-Aug-2022
US-20260152554-A1 Humanized antibodies against cd79b Pending 08-Aug-2022
WO-2024033362-A1 Humanized antibodies against cd79b Inactive 08-Aug-2022
EP-4479415-A1 Recombinant immunotoxin comprising a ribosome inactivating protein Pending 17-Feb-2022 A61K39/39558
To view atbtherapeutics’s complete patent history, request access »

atbtherapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

atbtherapeutics Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds
Carbon ( Belgium ) Venture Capital Minority
Directorate General for Economy Corporation Minority
EQT Life Sciences Venture Capital Minority
MRL Ventures Fund Corporate Venture Capital Minority
Société Fédérale de Participations et d'Investissement Holding Company Minority
You’re viewing 5 of 14 investors. Get the full list »

atbtherapeutics FAQs

  • When was atbtherapeutics founded?

    atbtherapeutics was founded in 2017.

  • Where is atbtherapeutics headquartered?

    atbtherapeutics is headquartered in Aye, Belgium.

  • What is the size of atbtherapeutics?

    atbtherapeutics has 36 total employees.

  • What industry is atbtherapeutics in?

    atbtherapeutics’s primary industry is Drug Discovery.

  • Is atbtherapeutics a private or public company?

    atbtherapeutics is a Private company.

  • What is the current valuation of atbtherapeutics?

    The current valuation of atbtherapeutics is .

  • What is atbtherapeutics’s current revenue?

    The current revenue for atbtherapeutics is .

  • How much funding has atbtherapeutics raised over time?

    atbtherapeutics has raised $66.1M.

  • Who are atbtherapeutics’s investors?

    Carbon ( Belgium ), Directorate General for Economy, EQT Life Sciences, MRL Ventures Fund, and Société Fédérale de Participations et d'Investissement are 5 of 14 investors who have invested in atbtherapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process